Highlights from the 2026 Bladder & Kidney Cancer Academy 

(co-hosted with Specialty Networks)

The 2026 Bladder & Kidney Cancer Academy, co-hosted by Specialty Networks and LUGPA, convened September 24–26 at the Westin Denver Airport, drawing participants from leading independent urology practices nationwide. Under the direction of Dr. Neal Shore and Dr. Tom Jayram, the Academy delivered an intensive multi-day agenda focused on clinical excellence, innovation, and collaboration in the management of kidney and bladder cancers.

The program featured expert-led sessions on localized and advanced renal cell carcinoma (RCC), risk stratification and emerging treatment options for non-muscle invasive bladder cancer (NMIBC), and contemporary approaches in muscle-invasive bladder cancer (MIBC). Attendees explored advances in molecular imaging, biomarkers, systemic immunotherapies, and radiation innovations shaping modern genitourinary oncology.

Interactive case discussions, faculty panels, debates, and industry updates from leading pharmaceutical and biotech partners provided real-world context and practical takeaways. Physicians engaged in robust dialogue about optimizing patient care pathways, managing immune-related adverse events, and integrating cutting-edge research into independent practice settings.

The Academy also provided valuable opportunities for networking among physicians, residents, and industry partners—strengthening relationships and fostering collaboration across the LUGPA and Specialty Networks communities.

To see highlights from this year's event, follow #bkca26 on social media.

Read about the 2025 event below . . . 

Leaders Unite at the 2025 Bladder & Kidney Cancer Academy

The 2025 Bladder & Kidney Cancer Academy, co-hosted by Specialty Networks and LUGPA, convened October 16–18 at the Hilton BNA in Nashville, drawing participants from leading independent urology practices nationwide. Under the direction of Dr. Neal Shore and Dr. Tom Jayram, the Academy delivered an intensive three-day agenda focused on clinical excellence, innovation, and collaboration in the management of kidney and bladder cancers. 

The program featured expert presentations on the latest treatment approaches for localized and advanced renal cell carcinoma, non–muscle invasive bladder cancer, and upper tract urothelial carcinoma. Attendees explored advances in imaging, systemic therapies, and biomarkers, as well as surgical and radiation innovations shaping the next decade of genitourinary oncology.

Interactive case discussions, panel debates, and industry updates from leading pharmaceutical and biotech partners provided real-world context and practical takeaways. Physicians engaged in robust dialogue about optimizing patient care pathways and integrating cutting-edge research into independent practice settings.

The Academy also provided an unparalleled opportunity for networking among physicians, residents, and industry partners—strengthening relationships and fostering collaboration across the LUGPA and Specialty Networks communities. As one of the year’s most anticipated specialty meetings, the Bladder & Kidney Cancer Academy reinforced its role as an essential forum for advancing patient outcomes and empowering independent urologists to lead the future of cancer care.

To see photos from the 2025 event, follow #BKCA25 on social media.